
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics Inc demonstrated a narrower net loss of $1.14 per share in 2Q25 compared to the original estimate of $1.22 per share, indicating improved financial performance. Additionally, the clinical trials for OKI-219 showcased a favorable safety profile, with reported adverse events limited to Grade 1 treatment-related issues and no interruptions or discontinuations, demonstrating the drug's promising tolerability. This combination of reduced financial losses and strong clinical trial results contributes to a positive outlook for the company's growth potential in the biopharmaceutical sector.
Bears say
OnKure Therapeutics Inc. is facing a projected full-year net loss of $4.56 per share for 2025, a slight improvement from an earlier estimate of $4.75 per share, yet still indicating a challenging financial outlook. The company encounters significant risks, including potential negative clinical results with its lead asset, OKI-219, as well as delays in advancing its pipeline candidates and obtaining necessary regulatory approvals. Furthermore, competitive pressures in the biopharmaceutical market and long-term dilution risks further exacerbate concerns regarding the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares